[Therapeutic strategies in idiopatic inflammatory myopathies].
Idiopathic inflammatory myopathies, such as polymyositis and dermatomyositis, share common clinical features such as progressive, symmetrical muscle weakness prevailing in the lower limbs, associated sometimes with muscle pains. High CK and typical biopsy insure the diagnosis. Possible causes for secondary myopathies and associated diseases should be actively investigated. The search for autoantibodies helps to better classify inflammatory myopathies and to better define the prognosis of the myopathy. Glucocorticoids are the cornerstone of the early phase therapy. Glucocorticoid-sparing agents, such as azathioprine and methotrexate, are second line agents but can be readily prescribed. In case of therapeutic resistance, a rescue treatment (ciclosporine, immunoglobulins, rituximab, cyclophosphamide) could be considered.
Chakour
Reza
R
Service d'immunologie et d'allergie, CHUV, 1011 Lausanne. Reza.Chakour@chuv.ch
Leimgruber
Annette
A
Bart
Pierre-Alexandre
PA
Spertini
François
F
D000293:Adolescent; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D003882:Dermatomyositis / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009220:Myositis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D017285:Polymyositis / Q000175:diagnosis / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone; D008727:Methotrexate